论文部分内容阅读
目的:探讨KAI1/CD82在喉癌组织中的表达水平及与患者临床病理特征的关系。方法:选取61例喉癌患者手术切除的病理组织标本(喉癌组)及61例癌旁组织标本(对照组),应用免疫组织化学法检测KAI1/CD82的表达水平。结果:喉癌组KAI1/CD82的表达水平低于对照组(P<0.05);肿瘤原发灶KAI1/CD82表达水平高于淋巴结转移灶(P<0.05);KAI1/CD82的表达水平与喉癌患者的淋巴结转移密切相关(P<0.05),但在不同年龄、临床分期及组织分化程度的患者之间的表达差异无统计学意义(P>0.05)。结论:KAI1/CD82的表达在喉癌的转移过程中具有一定作用,可作为预测肿瘤转移潜能的指标。
Objective: To investigate the expression of KAI1 / CD82 in laryngeal carcinoma and its relationship with clinicopathological features. Methods: Totally 61 pathological specimens of laryngeal carcinoma (laryngocarcinoma group) and 61 para-cancerous tissues (control group) were selected from 61 laryngeal cancer patients. The expression of KAI1 / CD82 was detected by immunohistochemistry. Results: The expression of KAI1 / CD82 in laryngeal carcinoma group was lower than that in control group (P <0.05). The expression level of KAI1 / CD82 in primary tumor was higher than that in lymph node metastasis (P <0.05) There was a significant correlation between lymph node metastasis and patient’s lymph node metastasis (P <0.05), but there was no significant difference between patients with different age, clinical stage and degree of differentiation (P> 0.05). Conclusion: The expression of KAI1 / CD82 plays a role in the metastasis of laryngeal carcinoma and can be used as an indicator of tumor metastasis potential.